Identifying Molecular Determinants of Prognosis in Advanced Squamous Cell Carcinoma
Immunotherapy is a crucial treatment for advanced squamous cell cancers that cannot be cured by surgery alone. But it works only half of the time, and we do not know why it fails in 50% of patients. This study will help to fill the knowledge gap by identifying predictors of immunotherapy response and failure, coupling novel spatial gene-expression profiling technology with advanced machine learning techniques.
— Kenneth K. Yu, M.D., Ph.D.
- Brigham and Women’s Hospital Harvard Medical School
- Clinical Career Development Award in Dermatologic Surgery
Related Articles
Exploring Gene Expression Patterns and Biomarkers of Disease Severity in Central Centrifugal Cicatricial Alopecia
Central centrifugal cicatricial alopecia (CCCA), which has been associated with uterine fibroids, is unlike other scarring alopecias because fibrosis rather…
Characterizing the Microbiome in Postmenopausal Women with Vulvar Lichen Sclerosus
Vulvar lichen sclerosus is a chronic inflammatory condition that leads to scarring, obliteration of normal vulvar architecture, dyspareunia, and significant…
Cell Signaling Changes Induced by Surgical Debulking May Improve Response to Smoothened Inhibitor Therapy
Smoothened (SMO) inhibitors, such as vismodegib, are effective treatments for locally advanced basal cell carcinomas (BCCs). However, recurrences are frequent…